Equities research analysts at Roth Capital assumed coverage on shares of AIT Therapeutics Inc (NASDAQ:AITB) in a research note issued on Monday. The brokerage set a “buy” rating and a $14.00 price target on the stock. Roth Capital’s price objective points to a potential upside of 143.48% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Laidlaw began coverage on shares of AIT Therapeutics in a research note on Thursday, August 24th. They set a “buy” rating and a $16.00 price target for the company. Ladenburg Thalmann Financial Services began coverage on shares of AIT Therapeutics in a research note on Monday, August 7th. They set a “buy” rating for the company.

COPYRIGHT VIOLATION WARNING: “AIT Therapeutics Inc (AITB) Now Covered by Analysts at Roth Capital” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/25/ait-therapeutics-inc-aitb-now-covered-by-analysts-at-roth-capital.html.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.

Receive News & Ratings for AIT Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.